Therapies to Decrease Severe Respiratory Syncytial Virus Illness
JAMA · 2024
DOI: 10.1001/jama.2024.7406 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Elizabeth A Scruggs-Wodkowski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Section, Ann Arbor VA Healthcare System, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Antiviral Agents, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This JAMA Insights discusses the use of monoclonal antibodies or protein-based vaccines to help prevent severe RSV infection in infants, children, and older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Section, Ann Arbor VA Healthcare System, Ann Arbor, Michigan.
- Department of Internal Medicine, Michigan Medicine, Ann Arbor.
- Deputy Editor, JAMA.
Zitieren
APA
Scruggs-Wodkowski, E. A., Malani, P. N., & Linder, K. A. (2024). Therapies to Decrease Severe Respiratory Syncytial Virus Illness. JAMA. https://doi.org/10.1001/jama.2024.7406
Vancouver
Scruggs-Wodkowski EA, Malani PN, Linder KA. Therapies to Decrease Severe Respiratory Syncytial Virus Illness. JAMA. 2024. doi:10.1001/jama.2024.7406
BibTeX
@article{ScruggsWodkowski2024,
author = {Scruggs-Wodkowski, Elizabeth A and Malani, Preeti N and Linder, Kathleen A},
title = {Therapies to Decrease Severe Respiratory Syncytial Virus Illness},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.7406}
}
EUVIMED